Want to see HK:2181 full AI Analyst Report?
2181 Stock Chart & Stats
HK$0.50
>-HK$0.01(-1.85%)
At close: 4:00 PM EST
HK$0.50
>-HK$0.01(-1.85%)
Day’s Range― - ―
52-Week RangeHK$0.31 - HK$0.81
Previous CloseN/A
Volume6.00K
Average Volume (3M)49.33K
Market Cap
HK$1.61B
Enterprise ValueHK$1.98K
Total Cash (Recent Filing)HK$93.31M
Total Debt (Recent Filing)HK$307.88M
Price to Earnings (P/E)16.2
Beta0.91
Next Earnings
Mar 31, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding4,124,080,000
10 Day Avg. Volume35,000
30 Day Avg. Volume49,333
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)11.77
Price to Sales (P/S)2.94
P/FCF Ratio-79.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong 2025 Revenue GrowthRevenue grew 48.5% in 2025 after prior years of losses, indicating a meaningful commercial turnaround and expanding sales base. If maintained, this scale can improve operating leverage and support further investment, although the pack does not establish that the pace will persist.
High Gross MarginsConsistently high gross margins indicate strong product economics and provide a substantial contribution pool before operating expenses. This can support reinvestment, resilience during moderate pricing pressure, and eventual margin expansion if the company scales revenue without matching cost growth.
Return To Net ProfitabilityThe return to positive net income represents a material improvement from deeply negative margins in 2021–2024. Sustained profitability would strengthen internal funding capacity and demonstrate that the business model can convert its strong gross economics into bottom-line earnings.
Bears Say
Elevated Balance-Sheet LeverageHigh leverage leaves equity relatively small compared with debt, reducing financial flexibility if earnings or cash flows weaken. It can also increase the importance of refinancing and interest obligations, limiting the company’s ability to fund growth or absorb operational setbacks comfortably.
Negative Free Cash FlowNegative free cash flow despite positive net income indicates that reported earnings are not yet translating into available cash after investment or working-capital needs. This weak conversion can constrain self-funded expansion and increase reliance on financing while the business develops.
Thin Operating ProfitabilityA very thin EBIT margin means the operating business has limited earnings protection if expenses rise or revenue growth slows. The contrast with strong gross margins suggests substantial costs below gross profit, while the company’s prior heavy losses underscore the still-developing durability of operations.
Mabpharm Limited News
2181 FAQ
What was Mabpharm Limited’s price range in the past 12 months?
Mabpharm Limited lowest stock price was HK$0.31 and its highest was HK$0.81 in the past 12 months.
What is Mabpharm Limited’s market cap?
Mabpharm Limited’s market cap is HK$1.61B.
When is Mabpharm Limited’s upcoming earnings report date?
Mabpharm Limited’s upcoming earnings report date is Mar 31, 2027 which is in 191 days.
How were Mabpharm Limited’s earnings last quarter?
Mabpharm Limited released its earnings results on Aug 28, 2026. The company reported HK$0.009 earnings per share for the quarter.
Is Mabpharm Limited overvalued?
According to Wall Street analysts Mabpharm Limited’s price is currently Overvalued.
Does Mabpharm Limited pay dividends?
Mabpharm Limited does not currently pay dividends.
What is Mabpharm Limited’s EPS estimate?
Mabpharm Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mabpharm Limited have?
Mabpharm Limited has 4,124,080,000 shares outstanding.
What happened to Mabpharm Limited’s price movement after its last earnings report?
Mabpharm Limited reported an EPS of HK$0.009 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Mabpharm Limited?
Currently, no hedge funds are holding shares in HK:2181
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mabpharm Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.83%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
15.45%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Mabpharm Limited
Mabpharm Limited is a Chinese biopharmaceutical firm dedicated to the research, development, and manufacturing of innovative and biosimilar medications. Its therapeutic focus areas include allergic conditions, various cancers, and autoimmune disorders. The company boasts a robust pipeline, with several key products currently in advanced Phase III clinical trials. These include CMAB007, a recombinant humanized anti-IgE monoclonal antibody targeting asthma; CMAB009, a recombinant anti-EGFR chimeric monoclonal antibody for the initial treatment of metastatic colorectal cancer; CMAB008, a recombinant anti-TNF-alpha chimeric monoclonal antibody designed for moderate to severe active rheumatoid arthritis; and CMAB807, an agent developed for osteoporosis. Furthermore, Mabpharm is progressing various candidates through Phase I clinical development. Among these are CMAB819, aimed at treating metastatic non-small cell lung cancer, hepatocellular carcinoma, and head and neck squamous cell carcinomas; CMAB807X, formulated for tumor bone metastasis; and CMAB809, which targets HER2 overexpressing breast cancer and metastatic gastric cancer. The preclinical pipeline is equally extensive, featuring CMAB810 for breast cancer; CMAB816, addressing periodic fever syndrome, lung cancer, and systemic juvenile idiopathic arthritis; and CMAB017, intended for KRAS wild-type colorectal cancer. Also in preclinical stages are biosimilar candidates such as CMAB015, an analog of secukinumab for plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis; CMAB018, a mepolizumab biosimilar for asthma and eosinophilic granulomatous polyangiitis; and CMAB022, designed for various inflammatory conditions. Beyond its product development, Mabpharm provides a range of related services, including contract research and development, technical consultation, technology transfer, and specialized technical support for biological products, diagnostic and chemical biological reagents, and pharmaceutical compounds. Established in 2018, Mabpharm Limited is headquartered in Taizhou, People's Republic of China.
Technical Analysis
Alphamab Oncology
―
RemeGen Co. Ltd. Class H
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―
SinoMab Bioscience Ltd.
―